Introduction
Patients, materials and methods
Database
Definitions
Quality assurance methods
Analysis of Ki-67
-
Immunohistochemical staining is conducted and the proportion of the malignant cells staining positive for the nuclear antigen Ki-67 is evaluated in a quantitative and visual way using light microscopes.
-
Ki-67 values are acquired as the percentage of positively marking malignant cells using the anti-human Ki-67 monoclonal antibody MIB1 which is one of the most commonly used antibodies and considered as the “gold standard” [19].
-
The Ki-67 percentage score is defined as the percentage of positively stained tumor cells among the total number of malignant cells assessed [11]. Withal only the positivity is of interest independent of the intensity of coloration. To ensure quality assurance of the staining, positive control tissues are completed.
-
The complete specimen is investigated and checked for immunostaining tumor cell nuclei. Scoring is conducted considering the whole tumor section and not only limiting to the hot spots of the carcinoma or to the most evident positive parts within the invasive segment or the front of necrosis.
Statistics
Results
Distribution of Ki-67 across different pathologies
Patients’ characteristics
Characteristic | Ki-67 (%) 1st quartile <10 % | Ki-67 (%) 2nd quartile 10–14 % | Ki-67 (%) 3rd quartile 15–24 % | Ki-67 (%) 4th quartile ≥25 % | Total n (%) |
P valuea
|
---|---|---|---|---|---|---|
Age (Mean ± SD) | 63.9 ± 12.5 | 63.0 ± 13.1 | 62.7 ± 13.2 | 60.3 ± 14.7 | 62.4 ± 13.5 | <0.001 |
Menopausal status | ||||||
Premenopausal | 131 (16.1 %) | 173 (20.4 %) | 216 (22.6 %) | 285 (27.4 %) | 805 (22.0 %) | <0.001 |
Postmenopausal | 683 (83.9 %) | 675 (79.6 %) | 739 (77.4 %) | 756 (72.6 %) | 2,853 (78.0 %) | |
Tumor size | ||||||
pT1 | 522 (66.3 %) | 499 (61.0 %) | 497 (54.1 %) | 437 (43.8 %) | 1,955 (55.5 %) | <0.001 |
pT2 | 209 (26.6 %) | 265 (32.4 %) | 337 (36.7 %) | 472 (47.3 %) | 1,283 (36.4 %) | |
pT3 | 26 (3.3 %) | 24 (2.9 %) | 41 (4.5 %) | 42 (4.2 %) | 133 (3.8 %) | |
pT4 | 30 (3.8 %) | 30 (3.7 %) | 43 (4.7 %) | 46 (4.6 %) | 149 (4.2 %) | |
Nodal status | ||||||
N0 | 549 (71.4 %) | 542 (57.7 %) | 524 (58.0 %) | 531 (54.8 %) | 2,146 (62.3 %) | <0.001 |
N1 | 160 (20.8 %) | 176 (22.0 %) | 223 (24.7 %) | 252 (26.0 %) | 811 (23.6 %) | |
N2 | 37 (4.8 %) | 49 (6.1 %) | 89 (9.9 %) | 102 (10.5 %) | 277 (8.0 %) | |
N3 | 23 (3.0 %) | 34 (4.2 %) | 67 (7.4 %) | 84 (8.7 %) | 208 (6.0 %) | |
Histology | ||||||
Ductal | 594 (73.0 %) | 644 (75.9 %) | 811 (84.9 %) | 964 (92.6 %) | 3,013 (82.4 %) | <0.001 |
Lobular | 122 (15.0 %) | 142 (16.7 %) | 121 (12.7 %) | 41 (3.9 %) | 426 (11.6 %) | |
Other | 98 (12.0 %) | 62 (7.3 %) | 23 (2.4 %) | 36 (3.5 %) | 219 (6.0 %) | |
Grading | ||||||
G1 | 309 (38.1 %) | 224 (26.5 %) | 103 (10.8 %) | 28 (2.7 %) | 664 (18.2 %) | <0.001 |
G2 | 469 (57.9 %) | 556 (65.8 %) | 676 (71.0 %) | 363 (35.1 %) | 2,064 (56.7 %) | |
G3 | 32 (4.0 %) | 65 (7.7 %) | 173 (18.2 %) | 643 (62.2 %) | 913 (25.1 %) | |
Lymphatic invasion | ||||||
L0 | 586 (77.9 %) | 570 (72.4 %) | 542 (61.4 %) | 504 (52.5 %) | 2,202 (65.1 %) | <0.001 |
L1 | 166 (22.1 %) | 217 (27.6 %) | 341 (38.6 %) | 456 (47.5 %) | 1,180 (34.9 %) | |
Vascular invasion | ||||||
V0 | 726 (97.3 %) | 748 (96.0 %) | 796 (93.0 %) | 841 (89.5 %) | 3,111 (93.7 %) | <0.001 |
V1 | 20 (2.7 %) | 31 (4.0 %) | 60 (7.0 %) | 99 (10.5 %) | 210 (6.3 %) | |
Estrogen receptor | ||||||
Positive | 790 (97.2 %) | 814 (96.0 %) | 885 (92.8 %) | 648 (62.3 %) | 3,137 (85.8 %) | <0.001 |
Negative | 23 (2.8 %) | 34 (4.0 %) | 69 (7.2 %) | 392 (37.7 %) | 518 (14.2 %) | |
Progesterone receptor | ||||||
Positive | 702 (86.3 %) | 761 (89.7 %) | 810 (84.9 %) | 550 (52.9 %) | 2,823 (77.2 %) | <0.001 |
Negative | 111 (13.7 %) | 87 (10.3 %) | 144 (15.1 %) | 490 (47.1 %) | 832 (22.8 %) | |
HER2/neu | ||||||
Positive | 69 (8.6 %) | 91 (10.9 %) | 168 (17.7 %) | 329 (31.9 %) | 657 (18.2 %) | <0.001 |
Negative | 737 (91.4 %) | 744 (89.1 %) | 779 (82.3 %) | 701 (68.1 %) | 2,961 (81.8 %) | |
Receptor status | ||||||
ER+ PR+ | 698 (85.9 %) | 757 (89.3 %) | 807 (84.6 %) | 525 (50.5 %) | 2,787 (76.3 %) | <0.001 |
ER+ PR− | 92 (11.3 %) | 57 (6.7 %) | 78 (8.2 %) | 123 (11.8 %) | 350 (9.6 %) | |
ER− PR+ | 4 (0.5 %) | 4 (0.5 %) | 2 (0.2 %) | 21 (2.0 %) | 31 (0.8 %) | |
ER− PR− | 19 (2.3 %) | 30 (3.5 %) | 67 (7.0 %) | 371 (35.7 %) | 487 (13.3 %) |
Ki-67 quartiles and histopathological parameters
Absolute Ki-67 values and histopathological parameters
Characteristic | Absolute Ki-67 mean (±SD) | Total n
|
P value
a
|
---|---|---|---|
Menopausal status | |||
Premenopausal | 24.1 (±20.4) | 805 | <0.001 |
Postmenopausal | 19.3 (±17.3) | 2,853 | |
Tumor size | |||
pT1 | 17.7 (±16.3) | 1,955 | <0.001 |
pT2 | 24.1 (±20.3) | 1,283 | |
pT3 | 20.7 (±15.7) | 133 | |
pT4 | 20.1 (±16.6) | 149 | |
Nodal status | |||
N0 | 18.9 (±17.9) | 2,146 | <0.001 |
N1 | 21.6 (±18.6) | 811 | |
N2 | 23.4 (±17.9) | 277 | |
N3 | 24.4 (±17.0) | 208 | |
Histology | |||
Ductal | 21.8 (±18.7) | 3,013 | <0.001 |
Lobular | 13.3 (±10.7) | 426 | |
Other | 14.5 (±17.5) | 219 | |
Grading | |||
G1 | 9.7 (±8.2) | 664 | <0.001 |
G2 | 16.2 (±12.7) | 2,064 | |
G3 | 37.4 (±22.1) | 913 | |
Lymphatic invasion | |||
L0 | 18.2 (±17.3) | 2,202 | <0.001 |
L1 | 24.3 (±18.9) | 1,180 | |
Vascular invasion | |||
V0 | 19.7 (±17.9) | 3,111 | <0.001 |
V1 | 27.8 (±19.9) | 210 | |
Estrogen receptor | |||
Positive | 16.8 (±14.1) | 3,137 | <0.001 |
Negative | 41.9 (±24.0) | 518 | |
Progesterone receptor | |||
Positive | 16.5 (±13.8) | 2,823 | <0.001 |
Negative | 33.5 (±24.1) | 832 | |
HER2/neu | |||
Positive | 27.5 (±19.0) | 657 | <0.001 |
Negative | 18.7 (±17.5) | 2,961 | |
Receptor status | |||
ER+ PR+ | 16.1 (±13.2) | 2,787 | <0.001 |
ER+ PR− | 21.9 (±19.1) | 350 | |
ER− PR+ | 40.6 (±27.4) | 31 | |
ER− PR− | 41.9 (±23.8) | 487 |
Prognostic value of Ki-67 and histopathological parameters in univariable survival analysis
Characteristic | Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95 % CI |
P ≤ | HR | 95 % CI |
P ≤ | |
Age (n = 3,658) | 1.05 | 1.05–1.06 | 0.001 | 1.07 | 1.06–1.08 | 0.001 |
Ki-67-categories (%) (n = 3,658) | ||||||
≤15 | 1 | 1 | ||||
16–25 | 1.24 | 0.95–1.61 | 0.11 | 1.26 | 0.94–1.69 | 0.12 |
26–35 | 2.02 | 1.52–2.69 | 0.001 | 2.12 | 1.55–2.90 | 0.001 |
36–45 | 2.00 | 1.34–2.98 | 0.001 | 2.12 | 1.37–3.26 | 0.001 |
>45 | 2.42 | 1.87–3.15 | 0.001 | 2.13 | 1.58–2.88 | 0.001 |
Menopausal status (n = 3,658) | ||||||
Premenopausal | 1 | 1 | ||||
Postmenopausal | 2.19 | 1.64–2.93 | 0.001 | 3.20 | 2.20–4.66 | 0.001 |
Tumor size (n = 3,520) | ||||||
pT1 | 1 | 1 | ||||
pT2 | 2.99 | 2.35–3.80 | 0.001 | 3.08 | 2.33–4.05 | 0.001 |
pT3 | 5.80 | 3.92–8.59 | 0.001 | 5.77 | 3.70–9.02 | 0.001 |
pT4 | 7.68 | 5.46–10.80 | 0.001 | 9.44 | 6.52–13.66 | 0.001 |
Nodal status (n = 3,442) | ||||||
N0 | 1 | 1 | ||||
N1 | 2.20 | 1.71–2.83 | 0.001 | 2.01 | 1.51–2.69 | 0.001 |
N2 | 3.23 | 2.34–4.46 | 0.001 | 2.92 | 2.02–4.23 | 0.001 |
N3 | 4.39 | 3.19–6.05 | 0.001 | 4.05 | 2.82–5.83 | 0.001 |
Histology (n = 3,658) | ||||||
Ductal | 1 | 1 | ||||
Lobular | 0.99 | 0.74–1.32 | 0.94 | 1.01 | 0.73–1.40 | 0.935 |
Other | 0.72 | 0.46–1.13 | 0.15 | 0.87 | 0.55–1.39 | 0.568 |
Grading (n = 3,641) | ||||||
G1 | 1 | 1 | ||||
G2 | 3.05 | 2.05–4.55 | 0.001 | 2.64 | 1.74–4.00 | 0.001 |
G3 | 5.00 | 3.33–7.50 | 0.001 | 4.04 | 2.63–6.19 | 0.001 |
Lymphatic invasion (n = 3,382) | ||||||
L0 | 1 | 1 | ||||
L1 | 2.55 | 2.07–3.14 | 0.001 | 2.31 | 1.83–2.92 | 0.001 |
Vascular invasion (n = 3,321) | ||||||
V0 | 1 | 1 | ||||
V1 | 3.27 | 2.49–4.29 | 0.001 | 2.72 | 1.98–3.75 | 0.001 |
Estrogen receptor (n = 3,655) | ||||||
Positive | 1 | 1 | ||||
Negative | 2.22 | 1.80–2.75 | 0.001 | 2.23 | 1.76–2.82 | 0.001 |
Progesterone receptor (n = 3,655) | ||||||
Positive | 1 | 1 | ||||
Negative | 2.18 | 1.80–2.65 | 0.001 | 2.14 | 1.72–2.66 | 0.001 |
HER2/neu (n = 3,618) | ||||||
Negative | 1 | 1 | ||||
Positive | 1.39 | 1.12–1.74 | 0.003 | 1.23 | 0.96–1.59 | 0.106 |
Receptor status (n = 3,655) | ||||||
ER+ PR+ | 1 | 1 | ||||
ER+ PR– | 1.86 | 1.40–2.47 | 0.001 | 1.79 | 1.30–2.47 | 0.001 |
ER− PR+ | 1.95 | 0.81–4.73 | 0.138 | 2.01 | 0.75–5.40 | 0.167 |
ER− PR− | 2.45 | 1.96–3.07 | 0.001 | 2.44 | 1.90–3.13 | 0.001 |
Prognostic value of Ki-67 and histopathological parameters in multivariable survival analysis
Characteristic | Disease-free survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95 % CI |
P ≤ | HR | 95 % CI |
P ≤ | |
Age | 1.05 | 1.04–1.07 | 0.001 | 1.07 | 1.06–1.09 | 0.001 |
Ki-67-categories (%) (n = 3,174) | ||||||
≤15 | 1 | 1 | ||||
16–25 | 1.00 | 0.72–1.39 | 1.00 | 1.14 | 0.78–1.66 | 0.49 |
26–35 | 1.44 | 0.97–2.12 | 0.07 | 1.71 | 1.10–2.65 | 0.017 |
36–45 | 1.50 | 0.91–2.48 | 0.11 | 2.05 | 1.18–3.55 | 0.011 |
>45 | 1.96 | 1.31–2.91 | 0.001 | 2.06 | 1.30–3.28 | 0.002 |
Menopausal status | ||||||
Premenopausal | 1 | 1 | ||||
Postmenopausal | 0.62 | 0.39–0.98 | 0.041 | 0.62 | 0.35–1.10 | 0.11 |
Tumor size | ||||||
pT1 | 1 | 1 | ||||
pT2 | 1.52 | 1.14–2.02 | 0.003 | 1.52 | 1.09–2.12 | 0.017 |
pT3 | 1.97 | 1.21–3.19 | 0.008 | 2.03 | 1.16–3.56 | 0.013 |
pT4 | 2.04 | 1.29–3.21 | 0.003 | 2.24 | 1.36–3.70 | 0.002 |
Nodal status | ||||||
N0 | 1 | 1 | ||||
N1 | 1.38 | 1.03–1.87 | 0.034 | 1.31 | 0.93–1.86 | 0.12 |
N2 | 1.88 | 1.29–2.74 | 0.001 | 1.97 | 1.28–3.04 | 0.002 |
N3 | 2.12 | 1.44–3.14 | 0.001 | 2.28 | 1.46–3.57 | 0.001 |
Histology | ||||||
Ductal | 1 | 1 | ||||
Lobular | 1.22 | 0.86–1.73 | 0.26 | 1.23 | 0.82–1.84 | 0.32 |
Other | 0.94 | 0.52–1.70 | 0.83 | 1.05 | 0.56–1.97 | 0.89 |
Grading | ||||||
G1 | 1 | 1 | ||||
G2 | 1.88 | 1.14–3.09 | 0.013 | 1.62 | 0.95–2.80 | 0.08 |
G3 | 1.96 | 1.12–3.41 | 0.018 | 1.46 | 0.79–2.67 | 0.23 |
Lymphatic invasion | ||||||
L0 | 1 | 1 | ||||
L1 | 1.20 | 0.91–1.59 | 0.20 | 1.04 | 0.75–1.43 | 0.82 |
Vascular invasion | ||||||
V0 | 1 | 1 | ||||
V1 | 1.44 | 1.04–2.01 | 0.030 | 1.28 | 0.87–1.89 | 0.21 |
Estrogen receptor | ||||||
Positive | 1 | 1 | ||||
Negative | 1.41 | 0.97–2.06 | 0.073 | 1.85 | 1.19–2.89 | 0.007 |
Progesterone receptor | ||||||
Positive | 1 | 1 | ||||
Negative | 1.39 | 0.99–1.95 | 0.056 | 1.29 | 0.87–1.93 | 0.21 |
HER2/neu | ||||||
Negative | 1 | 1 | ||||
Positive | 0.86 | 0.65–1.14 | 0.28 | 0.70 | 0.80–0.98 | 0.036 |
Ki-67 categories (%) | DFS rate | OS rate | ||
---|---|---|---|---|
3 years (%) | 5 years (%) | 3 years (%) | 5 years (%) | |
0–15 | 92.6 | 86.7 | 94.4 | 89.3 |
16–25 | 90.4 | 83.1 | 92.9 | 88.2 |
26-35 | 83.6 | 79.1 | 87.7 | 80.8 |
36–45 | 83.0 | 77.3 | 87.1 | 80.4 |
>45 | 79.0 | 75.8 | 85.0 | 82.8 |